CAI/II-IN-12

CAI/II-IN-12 is a potent and hCAI (IC50 = 7.12 μM, Ki = 9.26 μM) and hCAII (IC50 = 10.62 μM, Ki = 11.72 μM) dual inhibitor. CAI/II-IN-12 has a strong affinity for the active sites of CYP17A1, hCAI, and hCAII enzymes. Compound CAI/II-IN-12 exhibits rapid conformational stabilization, particularly in the CYP17A1 complex. CAI/II-IN-12 can be used for the study of prostate cancer therapy and glaucoma[1].

Product Specifications

UNSPSC

12352005

Target

Carbonic Anhydrase

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Cancer; Neurological Disease

Smiles

O=S(C1=CC=C(C)C=C1)(OC2=CC=CC(/C=N/N3C(CC4=CC=C(C)C=C4)=NN(C(C)=O)C3=O)=C2)=O

Molecular Formula

C26H24N4O5S

Molecular Weight

504.56

References & Citations

[1]Medetalibeyoğlu H, et al. Synthesis and Computational Evaluation of N Acetyl-Derived Schiff Bases Incorporating 1,2,4-Triazoles for Dual Inhibition of Prostate Cancer Cells and Carbonic Anhydrases. ACS Omega. 2025 Aug 22;10 (34) :38585-38608.